top of page
Browse by category
Search


Fractyl’s Rejuva platform demonstrates potent and durable effects of a single dose of a human GLP-1 pancreatic gene therapy transgene vs semaglutide for diabetes and obesity
Fractyl Health has revealed promising new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy...


Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM
Fractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...
Browse by tag





bottom of page